Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Prepayment or repayment of borrowings
Part of the fresh issue proceeds is earmarked for paying down borrowings taken by the company, which lowers interest cost and frees up the balance sheet.
Acquisitions and general corporate purposes
The balance of the fresh issue funds inorganic growth through acquisitions and other unallocated general corporate needs of the business.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Rubicon Research Limited is an Indian pharmaceutical formulations company that was set up in 1999 and works across the full research-to-production chain. Its focus is on differentiated products rather than plain generics: specialty formulations and drug-device combination products, built around its own research and development programme. The overwhelming majority of its revenue comes from the regulated United States market, where it sells both non-branded and branded products through subsidiaries that give it a direct sales and distribution footprint. The company runs two research and development centres, one in India and one in Canada, and manufactures at facilities in Ambernath and Satara in Maharashtra. Its plants and R&D sites have been inspected by the US Food and Drug Administration, and it also holds approvals from other international regulators. As of 30 June 2025 its portfolio ran to 72 US FDA-approved ANDA and NDA products, of which a commercialised subset drives revenue; the company has said it holds a share above 25 percent in the US market for seven of its products. Growth has been rapid in the recent reported periods. Revenue rose from about 419 crore rupees in FY23 to roughly 1,296 crore rupees in FY25, and the company moved from a loss in FY23 to a profit after tax of about 134 crore rupees in FY25. Its product-selection approach leans on data to pick molecules where it can build a defensible position, and the combination of in-house formulation research, US FDA-cleared manufacturing and an owned distribution channel in the United States is what the company presents as its principal growth engine. The concentration of its business in a single overseas market is the flip side of that model.
Ahead of the issue the company placed 1,27,64,691 equity shares with 38 anchor investors at 485 rupees per share, raising about 619 crore rupees. Domestic mutual funds took roughly 39 percent of the anchor book across 18 schemes. Participants included HDFC Mutual Fund, ICICI Prudential Mutual Fund, Kotak Mutual Fund, PGIM India Mutual Fund and Canara Robeco Mutual Fund, alongside Goldman Sachs Funds India Equity Portfolio, Amansa Holdings and Aranda Investments.
Source: RHP • Analysis provided for informational purposes
Last Updated: 13 July 2026, 5:30 AM
Differentiated product portfolio
The company sells specialty formulations and drug-device combination products rather than commodity generics, and reports a share above 25 percent in the US market for seven of its commercialised products.
In-house research across two countries
Research and development centres in India and Canada let the company originate and develop its own products, reducing dependence on third-party developers.
Owned US distribution
Subsidiaries in the United States give it a direct route to market for both branded and non-branded products instead of relying on a partner to sell for it.
Regulatory track record
Its facilities have cleared US FDA inspections and it holds approvals from other overseas regulators, which is a precondition for staying in the regulated markets it targets.
Rapid recent growth
Revenue roughly tripled between FY23 and FY25 and the company swung from a loss in FY23 to a profit after tax of about 134 crore rupees in FY25.
Dependence on one geography
The United States accounts for the bulk of revenue, so any adverse shift in that single market, including tariffs or pricing pressure, hits the business disproportionately.
Regulatory and quality exposure
A product recall, a failed inspection or a facility shutdown in a heavily regulated industry could interrupt supply and damage the approvals the business depends on.
Research may not pay off
Money spent on development does not reliably convert into approved, commercially successful products, so the growth pipeline is uncertain.
MUFG Intime India Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.
Competitive pressure on margins
The pharmaceutical formulations market is crowded, and competition can erode pricing and compress margins over time.
Currency movement
With revenue earned largely in dollars and costs partly in rupees, exchange rate swings feed directly into reported results.
Covenants on borrowings
Loan agreements carry restrictive conditions, and a breach could trigger early repayment demands at an inconvenient time.